Literature DB >> 33321086

Dosing of BRAK and MEK Inhibitors in Melanoma: No Point in Taking a Break.

Jenny H Lee1, Matteo S Carlino2, Helen Rizos3.   

Abstract

Resistance to BRAF/MEK inhibitor treatment occurs in most patients with advanced BRAFV600-mutant melanoma. Intermittent drug dosing had been proposed as a strategy to circumvent resistance. In a clinical trial published in Nature Medicine, continuous dosing of BRAF/MEK inhibitors produced superior progression-free survival compared to intermittent dosing in BRAFV600-mutant melanoma patients. Crown
Copyright © 2020. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33321086     DOI： 10.1016/j.ccell.2020.11.010

Source DB:  PubMed          Journal:  Cancer Cell        ISSN： 1535-6108            Impact factor:   31.743


  2 in total

1.  Bilirubin Restrains the Anticancer Effect of Vemurafenib on BRAF-Mutant Melanoma Cells Through ERK-MNK1 Signaling.

Authors:  Yufan Tan; Xiaoyu Zhong; Xizhi Wen; Leyi Yao; Zhenlong Shao; Wenshuang Sun; Jiawen Wu; Guanmei Wen; Daolin Tang; Xiaoshi Zhang; Yuning Liao; Jinbao Liu
Journal:  Front Oncol       Date:  2021-06-18       Impact factor: 6.244

2.  Paclitaxel anticancer activity is enhanced by the MEK 1/2 inhibitor PD98059 in vitro and by PD98059-loaded nanoparticles in BRAFV600E melanoma-bearing mice.

Authors:  Aml I Mekkawy; Youssef W Naguib; Suhaila O Alhaj-Suliman; Emad I Wafa; Kareem Ebeid; Timothy Acri; Aliasger K Salem
Journal:  Int J Pharm       Date:  2021-07-10       Impact factor: 6.510
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.